Literature DB >> 12644899

Enhanced adenosine A(2B) mediated coronary response in reserpinised rat heart.

Roselyn B Rose'Meyer1, Glenn J Harrison, John P Headrick.   

Abstract

In this study, we investigated the effect of noradrenaline depletion on contractile recovery in rat isolated heart following myocardial ischaemia. Groups tested included control tissues and hearts from reserpinised rats. Reserpine 1 mg/kg s.c. was injected into rats 18 to 24 h prior to experiments. Hearts underwent 15 min global normothermic ischaemia followed by 30 min reperfusion. Functional data (end diastolic pressure (EDP), heart rate (HR), left ventricular developed pressure (LVDP), dP/dt(max), dP/dt(min)) showed that contractile function following ischaemia-reperfusion is unaffected by reserpinisation. However, pre- and post-ischaemic coronary flow rates (CFR) were increased by 16 to 38% in hearts from reserpinised rats versus control hearts. Pre-ischaemic CFRs in control hearts (11.17+/-0.67 ml/in(-1) x g tissue(-1), n=9) were significantly lower then CFRs derived from reserpinised rat hearts (14.57+/-0.72 ml/min(-1)/g tissue(-1), n=10). Post-ischaemic reactive hyperaemia was evident in all groups. CFRs in reserpinised hearts remained elevated when compared to pre-ischaemic values through reperfusion (P<0.05). Reserpine treatment did not significantly alter pre- or post-ischaemic adenosine efflux. The A(2B) adenosine receptor antagonist alloxazine (10 microM) attenuated pre- and post-ischaemic CFRs in both control and reserpinised hearts (P<0.05) without altering the hyperaemic response while the A(2A) adenosine receptor antagonist 8-(3-chlorostyryl) caffeine (1 microM) did not alter CFRs in both groups. The A(3) adenosine receptor antagonist MRS1191 (0.1 microM) increased CFR in control and reserpinised hearts (P<0.05). Catecholamine depletion with reserpinisation enhances the responsiveness of the coronary resistance vessels to endogenous adenosine through activation of the A(2B) adenosine receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644899     DOI: 10.1007/s00210-002-0678-z

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  33 in total

1.  The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.

Authors:  C Zocchi; E Ongini; A Conti; A Monopoli; A Negretti; P G Baraldi; S Dionisotti
Journal:  J Pharmacol Exp Ther       Date:  1996-02       Impact factor: 4.030

2.  Age-related changes in adenosine in rat coronary resistance vessels.

Authors:  R B Rose'Meyer; F A Harden; J I Varela; G J Harrison; R J Willis
Journal:  Gen Pharmacol       Date:  1999-01

3.  Facilitative interactions between noradrenergic and purinergic signaling during preconditioning of the rat heart.

Authors:  C B Winter; J C Cleveland; K L Butler; D B Bensard; M B Mitchell; A H Harken; A Banerjee
Journal:  J Mol Cell Cardiol       Date:  1997-01       Impact factor: 5.000

4.  A method to evaluate the response of the coronary circulation of perfused rat heart to adenosine.

Authors:  G J Harrison; F A Harden; L R Jordan; J I Varela; R J Willis
Journal:  Can J Physiol Pharmacol       Date:  1996-02       Impact factor: 2.273

Review 5.  Noradrenaline and ATP: cotransmitters and neuromodulators.

Authors:  G Burnstock
Journal:  J Physiol Pharmacol       Date:  1995-12       Impact factor: 3.011

Review 6.  Adenosine receptor subtypes.

Authors:  M G Collis; S M Hourani
Journal:  Trends Pharmacol Sci       Date:  1993-10       Impact factor: 14.819

7.  Effect of beta-adrenergic blockade on nucleoside release from the hypoperfused isolated heart.

Authors:  R D Wangler; D F DeWitt; H V Sparks
Journal:  Am J Physiol       Date:  1984-08

8.  Endogenous catecholamines are not necessary for ischaemic preconditioning in the isolated perfused rat heart.

Authors:  E O Weselcouch; A J Baird; P G Sleph; S Dzwonczyk; H N Murray; G J Grover
Journal:  Cardiovasc Res       Date:  1995-01       Impact factor: 10.787

9.  The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist.

Authors:  S M Poucher; J R Keddie; P Singh; S M Stoggall; P W Caulkett; G Jones; M G Coll
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

10.  The binding of 1,3-[3H]-dipropyl-8-cyclopentylxanthine to adenosine A1 receptors in rat smooth muscle preparations.

Authors:  J A Peachey; S M Hourani; I Kitchen
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

View more
  5 in total

1.  Mediators of coronary reactive hyperaemia in isolated mouse heart.

Authors:  Amanda J Zatta; John P Headrick
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

2.  Cytoprotective effects of adenosine and inosine in an in vitro model of acute tubular necrosis.

Authors:  Katalin Módis; Domokos Gero; Nóra Nagy; Petra Szoleczky; Zoltán Dóri Tóth; Csaba Szabó
Journal:  Br J Pharmacol       Date:  2009-11       Impact factor: 8.739

3.  B-Myb regulates the A(2B) adenosine receptor in vascular smooth muscle cells.

Authors:  Cynthia St Hilaire; Dan Yang; Barbara M Schreiber; Katya Ravid
Journal:  J Cell Biochem       Date:  2008-04-15       Impact factor: 4.429

4.  Adenosine-mediated alteration of vascular reactivity and inflammation in a murine model of asthma.

Authors:  Dovenia S Ponnoth; Ahmed Nadeem; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-02-29       Impact factor: 4.733

5.  Adenosine and inosine exert cytoprotective effects in an in vitro model of liver ischemia-reperfusion injury.

Authors:  Katalin Módis; Domokos Gerő; Rita Stangl; Olivér Rosero; Attila Szijártó; Gábor Lotz; Petra Mohácsik; Petra Szoleczky; Ciro Coletta; Csaba Szabó
Journal:  Int J Mol Med       Date:  2012-12-04       Impact factor: 4.101

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.